SPY317.59+3.21 1.02%
DIA260.82+3.58 1.39%
IXIC10,617.44+69.69 0.66%

Cowen & Co. Downgrades Intercept Pharmaceuticals to Market Perform, Lowers Price Target to $47

Cowen & Co. analyst Ritu Baral downgrades Intercept Pharmaceuticals (NASDAQ:ICPT) from Outperform to Market Perform and lowers the price target from $149 to $47.

Benzinga · -
Cowen & Co. analyst Ritu Baral downgrades Intercept Pharmaceuticals (NASDAQ: ICPT) from Outperform to Market Perform and lowers the price target from $149 to $47.